^
    Back
    Association details:
    Biomarker:Chr del(11q)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Copiktra (duvelisib) (PI3Kδ inhibitor, PI3Kγ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

    Published date:
    11/06/2019
    Excerpt:
    DUV demonstrated a more favorable PFS than OFA in patients with either del(11q) (median PFS, 24.8 vs 9.2 months; HR, 0.34; P = .0318)….Patients with R/R CLL/SLL and del(11q), U-IGHV, or the absence of del(13q) demonstrated extended PFS and a higher ORR with DUV vs OFA in the second-line setting; therefore, these prognostic markers are potential identifiers of patients who would benefit from DUV treatment.
    DOI:
    https://doi.org/10.1182/blood-2019-122491